Clinical characteristics and treatment outcomes of gastric cancer patients with isolated para-aortic lymph node involvement

• Published in: Cancer chemotherapy and pharmacology Vol. 67; no. 1; pp. 127 - 136
• Main Authors: Park, In Hae, Kim, Sun Young, Kim, Young-Woo, Ryu, Keun Won, Lee, Jun Ho, Lee, Jong Seok, Park, Young-Iee, Kim, Noe Kyeong, Park, Sook Ryun
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer-Verlag 2011; Springer; Springer Nature B.V
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic agents; Antineoplastic Agents - therapeutic use; Biological and medical sciences; Cancer Research; Female; Gastroenterology. Liver. Pancreas. Abdomen; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Medical sciences; Medicine; Medicine & Public Health; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oncology; Original Article; Palliative Care - methods; Pharmacology. Drug treatments; Pharmacology/Toxicology; Retrospective Studies; Stomach Neoplasms - drug therapy; Stomach Neoplasms - pathology; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus; Survival; Time Factors; Tumors; Young Adult; Recurrent disease; Para-aortic lymph node; De novo metastasis; Advanced gastric cancer; Relapse; Prognosis; Disease; Metastasis; Stomach cancer; Blood vessel; Aorta; Advanced stage; Gastric disease; Human; Lymph node; Characteristic; Patient; Malignant tumor; Artery; De novo; Treatment; Adenopathy; Digestive diseases; Circulatory system; Cancer
• ISSN: 0344-5704; 1432-0843
• DOI: 10.1007/s00280-010-1296-y

Background Although gastric cancer with isolated para-aortic lymph node (PAN) involvement is considered an advanced disease, the clinical characteristics of it have not been comprehensively elucidated. Patients and methods We reviewed the medical records of 1,277 patients received palliative chemotherapy with advanced gastric cancer according to metastatic sites: PAN-only metastasis, single organ metastasis other than PAN, and multiple organ metastasis. Time to other organ metastasis (TTOM) was determined only in PAN-only metastasis group as the time interval between initial diagnosis of recurrence or de novo metastasis and confirming distant metastasis beyond PAN area. Results The median overall survival (OS) of patients with PAN-only metastasis was significantly longer than that of patients with single organ metastasis other than PAN or multiple organ metastasis (13.8 months vs. 11.4 months vs. 8.4 months; P  < 0.001). In the PAN-only metastasis group, patients with recurrent diseases showed longer TTOM beyond the PAN area (10.7 vs. 7.7 months; P  = 0.037) and OS (23.8 vs. 12.8 months; P  = 0.010) than those with de novo metastatic disease and it was validated by multivariate analysis. Conclusion Patients with isolated PAN metastasis showed an excellent prognosis compared with patients with metastasis at other sites and it was primarily evident in patients with recurrent PAN metastasis.